TLThomas Longval

Thomas Longval

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Thomas Longval has a total of 184 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Clinical Characteristics, Management and Outcomes of Nonintensive Care Unit Candidemia: Subanalysis of the ECMM Candida III Multinational European Observational Cohort Study

    by Stella Wolfgruber, Carolina Garcia-Vidal, Sarah Sedik, Jon Salmanton-García, Sevtap Arikan-Akdagli, Jean-Pierre Gangneux, Riina Rautemaa-Richardson, Valentina Arsić-Arsenijević, Sonia Martín-Pérez, Julio Dávila-Valls, et al.

    ECMM-Candida III was a pan-European, multicentre observational study of adult patients with blood culture-proven candidemia. Among a total of 632 patients with candidemia across 64 institutions in 20 European countries, a sub-analysis of 396 (63%) cases occurring outside the intensive care unit (ICU) was conducted. Compared with ICU-patients, non-ICU patients had a higher comorbidity burden (median Charlson Comorbidity Index [CCI] 6 vs. 5 in ICU patients, p=0.006). Hematologic and oncologic malignancies were more frequent among non-ICU cases (45.5%, vs 28.4%, pCandida scores were associated with lower mortality risk in the multivariable Cox regression models. In conclusion, despite higher co-morbidity rates, non-ICU patients with candidemia had higher survival rates.


  • Open Access

    Risk factors for persistent candidemia and prognostic implications: Results from the ECMM Candida III study

    by Sarah Sedik, Matthias Egger, Stella Wolfgruber, Jon Salmanton-García, Matteo Bassetti, Malgorzata Mikulska, Volkan Özenci, Sevtap Arikan-Akdagli, Murat Akova, Jean-Pierre Gangneux, et al.


  • Efficacy and safety of Daratumumab for the treatment of ABO-incompatible pure red cell aplasia after allogenic HSCT: report from SFGM-TC

    by Thomas Longval, Anne-Claire Leprêtre, Aurélie Ravinet, Amandine Fayard, Edouard Forcade, Tereza Coman, Rabah Redjoul, Ana Berceanu, Nimrod Buchbinder, Guillaume Berlie, et al.


  • Top Cited Papers

    Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study

    by Martin Hoenigl, Jon Salmanton-García, Matthias Egger, Jean-Pierre Gangneux, Tihana Bicanic, Sevtap Arikan-Akdagli, Ana Alastruey-Izquierdo, Nikolai Klimko, Aleksandra Barac, Volkan Özenci, et al.


  • Open Access

    Guideline Adherence Predicts Survival of Candidemia in Europe: Results from the ECMM Candida III Multinational European Study

    by Martin Hoenigl, Jon Salmanton-Garcia, Matthias Egger, Jean-Pierre Gangneux, Tihana Bicanic, Sevtap Arikan-Akdagli, Ana Alastruey-Izquierdo, Nikolai Klimko, Aleksandra Barac, Volkan Özenci, et al.

    Objectives: The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of culture proven candidemia across Europe in order to assess how adherence to guideline recommendations correlate with outcomes. Methods: Each participating hospital (number of eligible hospitals per country determined by population size) included the first ~10 culture proven candidemia cases after 01-July-2018 and entered data into the ECMM Candida III database on the FungiScope® platform. EQUAL Candida Scores reflecting adherence to recommendations of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Infectious Disease Society of America (IDSA) Guidelines were assessed. Results: A total of 632 candidemia cases were included from 60 institutions in 20 European countries. Overall mortality was 46.4% (286/617), and older age, intensive care unit (ICU) admission and rare Candida spp. as causative pathogens were independent predictors of mortality in Cox regression analysis. EQUAL Candida Score was evaluable for 589 cases with candidemia and remained an independent predictor of mortality in the multivariable Cox regression analyses after adjusting for age, ICU admission and rare Candida spp. (adjusted hazard ratios between 1.074 and 1.087 per 1 point decrease; p<0.001). Median duration of hospitalization was 16 days following diagnosis of candidemia and was prolonged specifically for completion of parenteral therapy in 16% (100/621) of patients. Initial echinocandin treatment was associated with a)lower overall mortality (42%, 148/353) versus those without initial echinocandin therapy (53%, 126/236; p=0.007), and b)longer duration of hospitalization among survivors (median 24 days, IQR 15-40 days vs. median 16 days, IQR 7-33 days; p<0.001). In those in whom candidemia was treated for at least 14 days, 78% (239/306) survived, compared to 66% (67/102) in those treated for less than 14 days, but who survived beyond day 14 from diagnosis. Conclusions: While overall mortality of candidemia was 46%, our study indicates that adherence to clinical guideline recommendations, reflected by higher EQUAL Candida Scores, may increase survival. Echinocandin treatment was associated with increased overall survival, but also longer duration of hospitalization (hospitalization was prolonged only for completing treatment in 16%). Funding Information: The study was funded by an Investigator Initiated Research Grant from Scynexis. Declaration of Interests: MH reports research funding from Astellas, Gilead, MSD, Pfizer, Euroimmun, and Scynexis. JSG has received lecture honoraria from Gilead and Pfizer, outside of the submitted work. TB reports receipt of speaker fees, advisory Board fees and research fellowship funding from Gilead sciences (funder for this study), research grants from Pfizer and MSD and advisory Board fees from Mundipharma. SAA reports research grant from Cidara, lecture honoraria from Gilead, and travel grant from Astellas. AA-I has received honoraria for educational talks of behalf of Gilead and Pfizer, outside of the submitted work. NK was a speaker for Astellas, Gilead Sciences, Merck/MSD, and Pfizer and an adviser for Gilead Sciences, Merck/MSD, and Pfizer, all outside the submitted work. KL received consultancy fees from MRM Health, MSD and Gilead, speaker fees from FUJIFILM WAKO, Pfizer and Gilead and a service fee from Thermo fisher Scientific and TECOmedical NK is a member of the Gilead, Merck Sharp & Dohme AG (MSD) and Pfizer advisory boards for invasive fungal infections, chair of the DSMB of Pulmicide, and reports grants from The Swiss National Science Foundation (grant number 32003B_204944 and the National Centre of Competence in Research AntiResist Grant 51NF40_180541), outside the submitted work. Outside the submitted work, MB reports research grants and/or personal fees for advisor/consultant and/or speaker/chairman from Bayer, BioMérieux, Cidara, Cipla, Gilead, Menarini, MSD, Pfizer, and Shionogi. BD reports receipt of speaker fees, advisory Board fees from Gilead sciences (funder for this study), advisory Board fees from Pfizer. 610 FD declares personal fees from Gilead, outside the submitted work. LD reports lecture honoraria from Pfizer, MSD and Teva, outside the submitted work Outside the submitted work, DRG reports investigator-initiated grants from Pfizer, Shionogi, and Gilead Italia and speaker fees and/or advisory board fees from Pfizer and Tillotts Pharma. AG reports COI with the following companies: JANNSEN, VIIV, MSD, BMS, ABBVIE, GILEAD, NOVARTIS, PFIZER, ASTELLAS, ASTRAZENECA, ANGELINI FL reports receipt of speaker fees from Gilead, Pfizer and F2G and advisory board fees from F2G Outside the submitted work, MM has received speaker fees from Janssen, Gilead, MSD and Pfizer ORI has received speaker's honorarium from Astellas, Pfizer and MSD. ER reports grants to his institutions from Astellas, MSD, Scynexis, Shionogi, GSK, Pfizer, Gilead and Allergan. He has served as consultant to Amplyx, Astellas, Gilead, MSD, Pfizer, Scynexis, GSK and Shionogi. JS has received lecture honoraria from Gilead and Pfizer, outside of the submitted work PLW: Performed diagnostic evaluations and received meeting sponsorship from Associates of Cape Cod, Bruker, Dynamiker, and Launch Diagnostics; Speaker’s fees, expert advice fees and meeting sponsorship from Gilead; and speaker and expert advice fees from Pfizer and expert advice fees from F2G BW reports personal fees from MSD, Pfizer, Gilead, Shionogi, Euroimmun, Immy, CapeCod and grants to her institution from Pfizer, Shionogi and AMT has received lecture honoraria from Gilead Maiken Cavling Arendrup has, over the past 5 years, received research grants/contract work (paid to the SSI) from Amplyx, Basilea, Cidara, F2G, Gilead, Novabiotics and Scynexis, and speaker honoraria (personal fee) from Astellas, Chiesi, Gilead, MSD, and SEGES. She is the...


  • Successful mRNA SARS-Cov-2 vaccine rechallenge after a first episode of immune thrombocytopenic purpura

    by Mathilde Chanut, Rym Jaidi, Milena Kohn, Thomas Grange, Clara Brones, Naëlle Lombion, Philippe Rousselot, Thomas Longval

    In 2021, the world experienced the most extensive vaccination campaign to defeat COVID-19. Many cases of idiopathic thrombocytopenia have been reported following injections of SARS-Cov-2 mRNA vaccine. We present the case of a 73-year-old woman with de novo ITP after a first injection of SARS-Cov-2 mRNA vaccine (Moderna vaccine) who experienced a successful rechallenge of SARS-Cov-2 mRNA vaccine (Pfizer vaccine) a few months later.


  • Treatment for pure red cell aplasia after major ABO‐incompatible allogeneic stem cell transplantation: a multicentre study

    by Thomas Longval, Jacques‐Emmanuel Galimard, Anne‐Claire Leprêtre, Felipe Suarez, Denise Amiranoff, Marine Cazaux, Eleonore Kaphan, David Michonneau, Nathalie Dhedin, Tereza Coman, et al.

    Summary: Pure red cell aplasia (PRCA) following allogeneic haematopoietic stem cell transplantation (aHSCT) with major ABO incompatibility is responsible for transfusion dependent anaemia, impaired quality of life and iron overload. We conducted a retrospective study, over a 10‐year period, which included all consecutive patients who received a major ABO mismatched aHSCT, to assess the impact of specific treatment on PRCA. We did not observe any PRCA in the 57 aHSCT issued from cord blood. Among the remaining 631 patients, cumulative incidence of PRCA was 10·5% [range 8·2–13.0]. The median duration of resolved PRCA was 171 days [IQR 116; 261]. Pre‐transplant high isohaemagglutinins titre was associated with an increased risk of PRCA (P < 10−4). PRCA did not affect overall survival (P = 0·95). Twenty‐two patients (33·3%) received at least one specific treatment. The most commonly used treatments were rituximab (17 patients) and donor lymphocyte infusion (DLI; seven patients). Regarding PRCA resolution, we did not observe a significant difference between treated or untreated subjects (HR = 0·93, 95% confidence interval (CI) 0·48– 1·80; P = 0·82). Similar results were observed with erythropoietin treatment (22 patients, HR = 0·86 95% CI: [0·47–1·57] P = 0·62). Our data do not support the use of erythropoietin, rituximab or DLI for the treatment of PRCA.


  • Open Access

    Two different patterns of lymphocyte alterations in critically ill COVID-19 patients

    by Antoine Lafarge, Jean-Edouard Martin, Thomas Longval, Thibault Dupont, Audrey De Jong, Elie Azoulay